Breaking News Instant updates and real-time market news.

TEVA

Teva

$30.17

-0.26 (-0.85%)

, BIP

Brookfield Infrastructure

$40.09

0.36 (0.91%)

10:48
06/16/17
06/16
10:48
06/16/17
10:48

On The Fly: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Teva (TEVA) upgraded to Neutral from Underperform at Mizuho with analyst Irina Koffler citing reduced near-term risk of a Mylan's (MYL) generic Copaxone approval, potential asset sale announcements, and encouraging May subscription trends. 2. Brookfield Infrastructure (BIP) upgraded to Outperform from Neutral at Credit Suisse with analyst Andrew Kuske saying the potential inclusion of Brookfield Infrastructure into the S&P Index is likely to have a "meaningful impact" on demand around the third quarter index revision. 3. Celgene (CELG) upgraded to Outperform from Market Perform at Leerink with analyst Geoffrey Porges saying he views Celgene's valuation as "discounted." 4. Regency Centers (REG) upgraded to Buy from Hold at Jefferies with analyst George Hoglund saying he believes the recent pullback in the shares creates an attractive entry point. 5. Nanometrics (NANO) upgraded to Buy from Hold at Stifel with analyst Patrick Ho citing valuation, along with his belief that wafer lab equipment spending will be strong next year and that the "elevated spending" level may be sustainable. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TEVA

Teva

$30.17

-0.26 (-0.85%)

BIP

Brookfield Infrastructure

$40.09

0.36 (0.91%)

CELG

Celgene

$120.61

-0.43 (-0.36%)

REG

Regency Centers

$61.95

-2.11 (-3.29%)

NANO

Nanometrics

$24.89

-0.91 (-3.53%)

  • 22

    Jun

  • 22

    Jun

  • 04

    Aug

  • 30

    Aug

TEVA Teva
$30.17

-0.26 (-0.85%)

06/16/17
CANT
06/16/17
INITIATION
Target $31
CANT
Neutral
Teva initiated with a Neutral at Cantor
Cantor Fitzgerald analyst Louise Chen started Teva with a Neutral rating and $31 price target.
06/15/17
MZHO
06/15/17
UPGRADE
MZHO
Neutral
Teva upgraded to Neutral from Underperform at Mizuho
Mizuho analyst Irina Koffler upgraded Teva (TEVA) to Neutral and raised its price target to $30 from $25 citing reduced near-term risk of a Mylan's (MYL) generic Copaxone approval, potential asset sale announcements, and encouraging May subscription trends. The analyst said challenging fundamentals have not changed but sees less downside risk over the next year.
05/11/17
WELS
05/11/17
NO CHANGE
WELS
Market Perform
Teva faces 'underappreciated risk' from major generic RFPs, says Wells Fargo
Wells Fargo analyst David Maris noted that Teva's generic drug price erosion came in at 7% in Q1, adding that Teva's management, which previously indicated that they expected price erosion in the U.S. to be 5%, "did not explain well" how the factors that negatively impacted prices were not fully anticipated. Also, there are currently two major generic Request for Proposals out for bid - one from Express Scripts (ESRX), Albertson's and Kroger (KR) and one from Walmart (WMT) and McKesson (MCK) - and the potential price reset from these is an "underappreciated risk" facing Teva, added Maris, who keeps a Market Perform rating on the stock.
05/02/17
LEHM
05/02/17
NO CHANGE
Target $70
LEHM
Overweight
Neurocrine price target raised to $70 from $60 at Barclays
Barclays analyst Geoff Meacham raised his price target for Neurocrine Biosciences (NBIX) to $70 and maintains an Overweight rating on the shares. Ingrezza pricing came in ahead of expectations at $50,000 per year net, Meacham tells investors in a research note. He believes the net cost of Ingrezza is favorably positioned relative to Teva's (TEVA) Austedo.
BIP Brookfield Infrastructure
$40.09

0.36 (0.91%)

12/09/16
12/09/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Chesapeake Utilities (CPK) initiated with a Neutral at Ladenburg. 2. CONSOL (CNX) initiated with a Neutral at Goldman. 3. Johnson Controls (JCI) assumed with an Equal Weight at Barclays. 4. American Midstream Partners (AMID) initiated with a Buy at Janney Capital. 5. Brookfield Infrastructure (BIP) coverage resumed with an Outperform at Wells Fargo. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/10/17
FBCO
02/10/17
DOWNGRADE
FBCO
Neutral
Brookfield Infrastructure downgraded to Neutral from Outperform at Credit Suisse
02/13/17
02/13/17
DOWNGRADE
Target $40

Neutral
Brookfield Infrastructure downgraded to Neutral at Credit Suisse
As previously reported, Credit Suisse analyst Andrew Kuske downgraded Brookfield Infrastructure to Neutral from Outperform, with a $40 price target, after media reports stated a Brazilian Federal Justice suspended the sale of the Petrobras's NTS gas pipeline system to the company. The analyst believes there will be legal wrangling ahead that will likely create timing uncertainty.
06/16/17
FBCO
06/16/17
UPGRADE
Target $44
FBCO
Outperform
Brookfield Infrastructure upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Andrew Kuske upgraded Brookfield Infrastructure Partners LP to Outperform and raised his price target shares to $44 from $40. The potential inclusion of Brookfield Infrastructure into the S&P Index is likely to have a "meaningful impact" on demand around the Q3 index revision, Kuske tells investors in a research note. The analyst also believes Brookfield ha a "solid fundamental organic growth story" that is underappreciated.
CELG Celgene
$120.61

-0.43 (-0.36%)

06/06/17
LEER
06/06/17
NO CHANGE
Target $100
LEER
Outperform
bluebird data among most impressive in CAR-T space, says Leerink
Leerink analyst Michael Schmidt says bluebird bio's (BLUE) bb2121 dose-escalation data in multiple myeloma is among the most impressive early data sets he's seen in the CAR-T space to date. The data sets a high bar for the competition, which includes Juno Therapeutics (JUNO), Kite Pharma (KITE) and Novartis (NVS), Schmidt tells investors in a research note. Being one year ahead of the competition provides bluebird and Celgene (CELG) with an ideal position in multiple myeloma, the analyst adds. He keeps an Outperform rating on bluebird shares with a $100 price target.
06/16/17
LEER
06/16/17
UPGRADE
Target $150
LEER
Outperform
Celgene upgraded to Outperform from Market Perform at Leerink
Leerink analyst Geoffrey Porges upgraded Celgene to Outperform and raised his price target for the shares to $150 from $146.
06/16/17
LEER
06/16/17
UPGRADE
Target $150
LEER
Outperform
Leerink upgrades Celgene to Outperform on 'discounted valuation'
Leerink analyst Geoffrey Porges upgraded Celgene to Outperform from Market Perform and raised his price target for the shares to $150 from $146. The biopharmaceutical company closed yesterday down 43c to $120.61. The analyst, who points out his revenue estimates for 2017-2019 are above the consensus, views Celgene's valuation as "discounted." The analyst expects the company's operating results to rebound in Q2 and stock's multiple to recover in Q3 "towards a more growth-appropriate range." He also anticipates "significant upward revisions" to consensus expectations in Q3.
06/13/17
06/13/17
NO CHANGE
Target $63

Outperform
FBR keeps $61 target on Acceleron after dalantercept failure
FBR Capital analyst Ed White says that while the dalantercept failed Phase II study is "disappointing," his focus remains on luspatercept, which is being studied in beta-thalassemia and myelodysplastic syndrome. Celgene (CELG) estimates peak sales potential of over $2B for luspatercept, which could translate into more than $400M in revenue for Acceleron Pharma (XLRN), White tells investors in a research note. He thinks luspatercept could be brought to market by 2019. White's price target for Acceleron remains $63 as he had only a 15% probability of approval and a low revenue estimate for dalantercept. The analyst reiterates an Outperform rating on the shares.
REG Regency Centers
$61.95

-2.11 (-3.29%)

05/10/17
RHCO
05/10/17
NO CHANGE
RHCO
Regency Centers reported 'strong' results, says SunTrust
SunTrust analyst Ki Bin Kim,says that Regency reported "strong" results, driven by a 3.7% increase in its SSNOI, "stable occupancy," and cost synergies. The analyst notes that the company's raised FFO guidance exceeded expectations ,and Kim is most impressed by the company's new top 25 tenant list. According to Kim, the list is "so much stronger" than those of other REIts. The analyst keeps a $77 price target and a Buy rating on the shares.
03/06/17
03/06/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Snap (SNAP) initiated with an Underperform at Needham. 2. Johnson Controls (JCI) initiated with a Neutral at JPMorgan. 3. Regency Centers (REG) reinstated with an Equal Weight at Barclays. 4. Limbach Holding (LMB) initiated with a Buy at Roth Capital. 5. Enbridge (ENB) coverage resumed with an Outperform at BMO Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/06/17
LEHM
03/06/17
INITIATION
Target $72
LEHM
Equal Weight
Regency Centers reinstated with an Equal Weight at Barclays
Barclays analyst Linda Tsai reinstated Regency Centers with an Equal Weight rating and $72 price target.
06/16/17
JEFF
06/16/17
UPGRADE
Target $74
JEFF
Buy
Regency Centers upgraded to Buy from Hold at Jefferies
Jefferies analyst George Hoglund upgraded Regency Centers to Buy and raised his price target for the shares to $74 from $72. The analyst believes the recent pullback in the shares creates an attractive entry point. He expects the company's grocery-anchored portfolio to outperform REIT peers.
NANO Nanometrics
$24.89

-0.91 (-3.53%)

06/16/17
STFL
06/16/17
UPGRADE
STFL
Buy
Nanometrics upgraded on valuation, wafer equipment spending outlook at Stifel
As noted earlier, Stifel upgraded Nanometrics to Buy from Hold. Analyst Patrick Ho upgraded the stock based on valuation, along with his belief that wafer lab equipment spending will be strong next year and that the "elevated spending" level may be sustainable. Target to $31 from $29.
05/03/17
DADA
05/03/17
NO CHANGE
DADA
Nanometrics should be bought on any weakness, says DA Davidson
After Nanometrics reported in-line revenue but its Q1 EPS and Q2 EPS guidance came in below expectations, DA Davidson analyst Thomas Diffely blames the miss on costs associated with the company's newer products. He notes that the company raised its 2017 revenue growth outlook to 18% from 13%. He raised his price target on the shares to $36 from $34 and keeps a Buy rating.
06/16/17
STFL
06/16/17
UPGRADE
STFL
Buy
Nanometrics upgraded to Buy from Hold at Stifel
03/22/17
DADA
03/22/17
NO CHANGE
DADA
Nanometrics outlook has improved, says DA Davidson
After meeting with Nanometrics' management, DA Davidson analyst Thomas Diffely says that the fundamentals of the company and its industry are improving. He says that the company's strong order book, a new OCD product and steady growth in the high margin software business should help the company report strong 2017 results. He thinks that the company's EPS could easily reach $2 in a few years. He raised his price target on the name to $34 from $30 and keeps a Buy rating.

TODAY'S FREE FLY STORIES

WLKP

Westlake Chemical Partners

$24.00

0.05 (0.21%)

16:09
09/26/17
09/26
16:09
09/26/17
16:09
Hot Stocks
Westlake Chemical Partners to acquire extra 5% interest in OpCo »

Westlake Chemical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LNDC

Landec

$12.55

0.6 (5.02%)

16:08
09/26/17
09/26
16:08
09/26/17
16:08
Earnings
Landec reports Q1 EPS 8c, consensus 6c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

MU

Micron

$34.18

-0.69 (-1.98%)

16:08
09/26/17
09/26
16:08
09/26/17
16:08
Technical Analysis
Technical View: Micron spikes higher after earnings beat »

In the extended session…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

MU

Micron

$34.18

-0.69 (-1.98%)

16:07
09/26/17
09/26
16:07
09/26/17
16:07
Hot Stocks
Micron CEO expects healthy industry fundamentals to continue into 2018 »

"Micron delivered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

AMSC

AMSC

$4.03

0.01 (0.25%)

16:06
09/26/17
09/26
16:06
09/26/17
16:06
Hot Stocks
AMSC completes acquisition of Infinia Technology »

AMSC announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

16:06
09/26/17
09/26
16:06
09/26/17
16:06
Hot Stocks
Micron says Q4 margin increase due to DRAM products »

Revenues for the fourth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

GFF

Griffon

$21.55

0.55 (2.62%)

, EMR

Emerson

$63.13

-0.48 (-0.75%)

16:06
09/26/17
09/26
16:06
09/26/17
16:06
Hot Stocks
Griffon amends ClosetMaid purchase agreement »

Griffon Corporation (GFF)…

GFF

Griffon

$21.55

0.55 (2.62%)

EMR

Emerson

$63.13

-0.48 (-0.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

AVGR

Avinger

$0.21

-0.0211 (-9.13%)

16:04
09/26/17
09/26
16:04
09/26/17
16:04
Hot Stocks
Avinger receives CE Marking approval for in-stent restenosis treatment »

Avinger announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLBD

Blue Bird

$18.85

0.2 (1.07%)

16:03
09/26/17
09/26
16:03
09/26/17
16:03
Hot Stocks
Blue Bird enters stock repurchase agreement with Coliseum Capital »

Blue Bird Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

AMGN

Amgen

$185.60

-0.69 (-0.37%)

, SCR

Simcere

16:03
09/26/17
09/26
16:03
09/26/17
16:03
Hot Stocks
Amgen and Simcere execute agreement to co-develop four biosimilars in China »

Amgen (AMGN) and Simcere…

AMGN

Amgen

$185.60

-0.69 (-0.37%)

SCR

Simcere

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

  • 02

    Dec

  • 03

    Feb

  • 30

    Apr

  • 17

    May

ITCI

Intra-Cellular

16:02
09/26/17
09/26
16:02
09/26/17
16:02
Syndicate
Intra-Cellular files to sell $150M in common stock »

J. P. Morgan Securities…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

MU

Micron

16:01
09/26/17
09/26
16:01
09/26/17
16:01
Earnings
Micron reports Q4 EPS $2.02 , consensus $1.84 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

SIEGY

Siemens

$68.96

-0.81 (-1.16%)

, ALSMY

Alstom

$3.91

-0.045 (-1.14%)

15:58
09/26/17
09/26
15:58
09/26/17
15:58
Hot Stocks
Siemens, Alstom confirm agreement to combine mobility businesses »

Siemens (SIEGY) and…

SIEGY

Siemens

$68.96

-0.81 (-1.16%)

ALSMY

Alstom

$3.91

-0.045 (-1.14%)

GE

General Electric

$24.97

-0.145 (-0.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

HII

Huntington Ingalls

$222.73

2.25 (1.02%)

15:50
09/26/17
09/26
15:50
09/26/17
15:50
Hot Stocks
Huntington Ingalls partners with Ivis to develop compliance software »

Huntington Ingalls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JD

JD.com

$40.93

-1.44 (-3.40%)

15:50
09/26/17
09/26
15:50
09/26/17
15:50
Options
JD options volume is 2.5X daily average and calls outpace puts 4:1 »

JD options volume is 2.5X…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$171.00

-8 (-4.47%)

, INTC

Intel

$37.16

-0.02 (-0.05%)

15:42
09/26/17
09/26
15:42
09/26/17
15:42
Periodicals
Breaking Periodicals news story on Nvidia, Intel, Tesla »

Tesla shifting from…

NVDA

Nvidia

$171.00

-8 (-4.47%)

INTC

Intel

$37.16

-0.02 (-0.05%)

TSLA

Tesla

$344.99

-6.1 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 05

    Oct

  • 08

    Oct

  • 22

    Oct

AMZN

Amazon.com

$939.79

-15.31 (-1.60%)

, TWLO

Twilio

$28.86

-0.615 (-2.09%)

15:38
09/26/17
09/26
15:38
09/26/17
15:38
Hot Stocks
Amazon discussses launch of AWS Global SMS two-way text messaging »

Amazon's (AMZN)…

AMZN

Amazon.com

$939.79

-15.31 (-1.60%)

TWLO

Twilio

$28.86

-0.615 (-2.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 08

    Oct

  • 22

    Oct

LNDC

Landec

$11.95

-0.3 (-2.45%)

15:34
09/26/17
09/26
15:34
09/26/17
15:34
Options
Landec options imply 12.6% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

T

AT&T

$38.80

-0.32 (-0.82%)

15:30
09/26/17
09/26
15:30
09/26/17
15:30
Periodicals
AT&T's DirecTV to allow 'some' refunds after anthem strife, WSJ says »

Certain subscribers to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 29

    Nov

AMJ

American Medical Laboratories Inc

$28.50

0.01 (0.04%)

15:30
09/26/17
09/26
15:30
09/26/17
15:30
Options
Alerian MLP attracts a bullish option play »

Alerian MLP attracts a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$85.47

-1.105 (-1.28%)

15:27
09/26/17
09/26
15:27
09/26/17
15:27
Hot Stocks
AbbVie says will take one single digit price increase for 2018 »

AbbVie issued the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 08

    Nov

STZ

Constellation Brands, also tag STZ.B

$200.37

-0.24 (-0.12%)

15:25
09/26/17
09/26
15:25
09/26/17
15:25
Options
Constellation Brands call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Oct

$NSD

NASDAQ Market Internals

15:17
09/26/17
09/26
15:17
09/26/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
09/26/17
09/26
15:16
09/26/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:15
09/26/17
09/26
15:15
09/26/17
15:15
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.